Radiation Therapy Oncology Group 0521: A Phase III Randomized Trial of Androgen Suppression and Radiation Therapy Versus Androgen Suppression and Radiation Therapy Followed by Docetaxel/Prednisone for Localized, High-Risk Prostate Cancer

Risk Prostate Cancer ◽

A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2015.05.024 ◽

2015 ◽

Vol 93 (2) ◽

pp. 294-302 ◽

Cited By ~ 36

Author(s):

Seth A. Rosenthal ◽

Daniel Hunt ◽

A. Oliver Sartor ◽

Kenneth J. Pienta ◽

Leonard Gomella ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Radiation Therapy Oncology Group ◽

Oncology Group ◽

Phase 3 ◽

Risk Prostate Cancer ◽

A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4632 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4632-4632 ◽

Cited By ~ 3

Author(s):

H. M. Sandler ◽

D. Hunt ◽

A. O. Sartor ◽

L. G. Gomella ◽

A. Hartford ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Phase Iii ◽

Risk Prostate Cancer ◽

Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2008.05.020 ◽

2009 ◽

Vol 73 (3) ◽

pp. 672-678 ◽

Cited By ~ 52

Author(s):

Seth A. Rosenthal ◽

Kyoungwha Bae ◽

Kenneth J. Pienta ◽

Mark L. Sobczak ◽

Sucha O. Asbell ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase Iii ◽

Oral Etoposide ◽

Risk Prostate Cancer ◽

Toxicity Analysis ◽

Radiotherapy Alone ◽

Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy

Practical Radiation Oncology ◽

10.1016/j.prro.2017.01.003 ◽

2017 ◽

Vol 7 (4) ◽

pp. 264-269 ◽

Cited By ~ 5

Author(s):

Sergio Faria ◽

Russel Ruo ◽

Fabio Cury ◽

Marie Duclos ◽

Luis Souhami

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Cancer Patients ◽

Late Toxicity ◽

Pelvic Radiation ◽

Risk Prostate Cancer ◽

A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-153 in Localized, High-Risk, Prostate Cancer

10.21236/ada443002 ◽

2005 ◽

Author(s):

Richard K. Valicenti

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Phase Ii ◽

Phase Ii Trial ◽

Risk Prostate Cancer ◽

Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02

Yearbook of Oncology ◽

10.1016/s1040-1741(09)79440-0 ◽

2010 ◽

Vol 2010 ◽

pp. 98-99

Author(s):

C.A. Lawton

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase Iii ◽

Oral Etoposide ◽

Risk Prostate Cancer ◽

Toxicity Analysis ◽

Radiotherapy Alone ◽

Hypofractionated Intensity Modulated Radiation Therapy to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2018.06.354 ◽

2018 ◽

Vol 102 (3) ◽

pp. S146 ◽

Cited By ~ 1

Author(s):

S.L. Faria ◽

F. Cury ◽

M. Duclos ◽

L. Souhami

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Intensity Modulated Radiation Therapy ◽

Intensity Modulated ◽

Risk Prostate Cancer ◽

Clinical Outcomes of the CHIRP Trial: A Phase II Prospective Randomized Trial of Conventionally Fractionated Versus Moderately Hypofractionated Prostate and Pelvic Nodal Radiation Therapy in Patients With High-Risk Prostate Cancer

Practical Radiation Oncology ◽

10.1016/j.prro.2021.02.011 ◽

2021 ◽

Author(s):

Michael H. Wang ◽

Larissa J. Vos ◽

Don Yee ◽

Samir Patel ◽

Nadeem Pervez ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Randomized Trial ◽

Clinical Outcomes ◽

Phase Ii ◽

Prospective Randomized Trial ◽

Risk Prostate Cancer ◽

Conventionally Fractionated

Abstract CT257: Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study Protocol

10.1158/1538-7445.am2021-ct257 ◽

2021 ◽

Author(s):

Jeremie Calais ◽

Shaojun Zhu ◽

Nader Hrimas ◽

Matthias Eiber ◽

Boris Hadaschik ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Randomized Trial ◽

Intermediate Risk ◽

Phase 3 ◽

Psma Pet ◽

Pet Ct ◽

Risk Prostate Cancer

A Prospective Phase III Randomized Trial of Hypofractionation Versus Conventional Fractionation in Patients With High-Risk Prostate Cancer: In Regard to Arcangeli C, et al. (Int J Radiat Oncol Biol Phys 2010;78:11–18)

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2010.12.013 ◽

2011 ◽

Vol 80 (1) ◽

pp. 316 ◽

Cited By ~ 2

Author(s):

Ivan R. Vogelius ◽

Søren M. Bentzen

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Randomized Trial ◽

Radiat Oncol Biol Phys ◽

Phase Iii ◽

Conventional Fractionation ◽

Risk Prostate Cancer ◽

Prospective Phase